RE: Nice little 570k bought at 1.73 1.74 appx26 Feb 2021 17:24
I don't know how Tony could be described as hit and miss, he basically just told us broad charting facts such as that we were trending up a penny a day for a month or when we lost support and therefore may see a sudden drop. His sort of charting isn't about being right or wrong, it's about assessing the likelihood of a rise or fall and acting on it accordingly (as a trader).
Tiger 'called' Arb during the biggest bitcoin bull market and then went on to suggest every share with any blockchain link. Light and day.
RE: French prime minister briefing now25 Feb 2021 20:11
It's frustrating tha we start the p3 just weeks before cases drop off a cliff. If we do an interim analysis on just the UK arm do you think we'll get an rns confirming p3 uk arm completion/ interim analysis in progress?
RE: French prime minister briefing now25 Feb 2021 18:26
'We can give you interferons up your arse, up your arse. We can give you interferons up your arse, up your arse. We would let you breathe them deep in but SNG have a patent, we can give you interferons up your arse!'
I don't think it would affect it. Vaccines reduce the chance of illness leading to hospitalisation in those that go on to catch it but I don't think once you're at the stage that you need oxygen that it makes any difference. Would be more of an issue for the home trial.
God knows where the sp could end up if everyone keeps setting such silly and unattainable targets and deadlines. ***************** I didn't know this BB could shift a £350m mcap company so much! Positive thoughts guys.
Mikeb, not an easy question to answer. Imo whilst we wait for news about £9. If contract news lands that is both large in number and long in scope (two years+) then we will quickly see new all time highs. Gl!
In regards to the share price, I know with hindsight it's easy to say this but there is reason to see why we're at 166p and not 250p. This is a risky investment with clearly defined timelines. Your average investor (and II) will not overexpose themselves to something that has ~30% chance of a sp collapse, at least theoretically (we believe it's more derisked than that). As of now, Polar is the glaring exception. Once the activ 2 news landed there was a general resignation on here that we now might not hear anything for six to eight weeks (Q2 for home trial results, around the same time for activ news). Of course surprising news is always possible but with this share that happens very, very rarely.
We know for certain that Q2 delivers plenty of important news... from about mid March those who don't want to miss out will start buying in or buying back in. It's at that point we'll get a picture of how much appetite there is for SNG.
Matml, my point is we can't claim double standards when it comes to therapeutics at the very least. If leronlimab, or regeneron, or camostat mesylate were approved having been tested on 100 patients then I really would be up in arms. But that isn't the case. The word 'data' pops out of RM's mouth more regularly than 'and' and 'the' so he knows how vital that is. As of one year into the pandemic, all we have is the p2 data set hospital arm to hand.